Overcoming barriers to adherence to HPV vaccination recommendations

American Journal of Managed Care

Volumn 12, Issue SUPPL. 17, 2006, Pages

  Dempsey, Amanda F ^a   Davis, Matthew M ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; WART VIRUS VACCINE;

ARTICLE; ATTITUDE TO HEALTH; CANCER PREVENTION; CONDYLOMA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH BEHAVIOR; HUMAN; INFECTION PREVENTION; PARENTAL ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; VIRUS TRANSMISSION; WART VIRUS;

ADOLESCENT; HUMANS; IMMUNIZATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; UNITED STATES;

EID: 33846015519     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265.
2. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, Pa: Churchill Livingstone; 2005.
3. Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. 2004;22:2943-2952.
4. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.
5. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
6. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284-292.
7. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-1651.
8. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.
9. US Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Available at: http://www.fda.gov/bbs/topics/news/2006/ new01385.html. Accessed November 22, 2006.
10. Mays RM, Zimet GD, Winston Y, Kee R, Dickes J, Su L. Human papillomavirus, genital warts, Rap smears, and cervical cancer: knowledge and beliefs of adolescent and adult women. Health Care Women Int. 2000; 21:361-374.
11. Baer H, Allen S, Braun L. Knowledge of human papillomavirus infection among young adult men and women: implications for health education and research. J Community Health. 2000;25:67-78.
12. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol. 2000;96:653-656.
13. Pitts M, Clarke T. Human papillomavirus infections and risks of cervical cancer: what do women know? Health Educ Res. 2002;17:706-714.
14. Vail-Smith K, White DM. Risk level, knowledge, and preventive behavior for human papillomaviruses among sexually active college women. J Am Coll Health. 1992;40:227-230.
15. Ramirez JE, Ramos DM, Clayton L, Kanowitz S, Moscicki AB. Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a nonclinic population of young women. J Womens Health. 1997;6:113-121.
16. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188-194.
17. Lazcano-Ponce E, Rivera L, Arillo-Santillan E, Salmeron J, Hernandez-Avila M, Munoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res. 2001;32:243-247.
18. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 2004;58:1405-1413.
19. Zimet GD, Mays RM, Sturm LA, Ravert AA, Perkins SM, Juliar BE. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch Pediatr Adolesc Med. 2005;159:132-137.
20. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486-1493.
21. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health. 2005;37:248-251.
22. Zimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE, Mays RM. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health. 2005;37:179-186.
23. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ. 2003;52:1-24.
24. Allred NJ, Shaw KM, Santibanez TA, Rickert DL, Santoli JM. Parental vaccine safety concerns: results from the National Immunization Survey, 2001-2002. Am J Prev Med. 2005;28:221-224.
25. Hilton S, Petticrew M, Hunt K. Combined vaccines are like a sudden onslaught to the body's immune system: parental concerns about vaccine overload and immune-vulnerability. Vaccine. 2006;24: 4321-4327.
26. Salmon DA, Moulton LH, Omer SB, DeHart MP, Stokley S, Halsey NA. Factors associated with refusal of childhood vaccines among parents of school-aged children: a case-control study. Arch Pediatr Adolesc Med. 2005;159:470-476.
27. Poland GA, Jacobson RM. Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine. 2001;19:2440-2445.
28. Francois G, Duclos P, Margolis H, et al. Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J. 2005;24:953-961.
29. Afzal MA, Ozoemena LC, O'Hare A, Kidger KA, Bentley ML, Minor PD. Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK. J Med Virol. 2006;78:623-630.
30. Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps, and rubella in children. Cochrane Database Syst Rev. 2005;(4):CD004407.
31. Koppen S, de Groot R, Neijens HJ, Nagelkerke N, van Eden W, Rumke HC. No epidemiological evidence for infant vaccinations to cause allergic disease. Vaccine. 2004;22:3375-3385.
32. Davis MM, Zimmerman JL, Wheeler JRC, Freed GL. Childhood vaccine purchase costs in the public sector: past trends, future expectations. Am J Public Health. 2002;92:1982-1987.
33. Institute of Medicine. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: National Academies Press; 2004.
34. Kaiser Family Foundation. HPV, cervical cancer, and the new vaccine. Available at: http://www.kaiseredu.org/ topics_im.asp?parentID= 72&imID=1&id=609#Costs. Accessed September 30, 2006.
35. Davis MM, Ndiaye SM, Freed GL, Kim CS, Clark SJ. Influence of insurance status and vaccine cost on physicians' administration of pneumococcal conjugate vaccine. Pediatrics. 2003;112:521-526.
36. Davis MM, Fant KE. Coverage of vaccines in private health plans: what does the public prefer? Health Aff (Millwood). 2005;24:770-779.
37. Smith PJ, Santoli JM, Chu SY, Ochoa DQ, Rodewald LE. The association between having a medical home and vaccination coverage among children eligible for the Vaccines for Children program. Pediatrics. 2005;116: 130-139.
38. Freed GL, Cowan AE, Clark SJ, Santoli J, Bradley J. Use of a new combined vaccine in pediatric practices. Pediatrics. 2006;118:e251-e257.
39. Woodwell DA, Cherry DK. National Ambulatory Medical Care Survey: 2002 Summary. Advance Data from Vital and Health Statistics; no 346. Hyattsville, Md: National Center for Health Statistics; 2004.
40. Humiston SG, Rosenthal SL. Challenges to vaccinating adolescents: vaccine implementation issues. Pediatr Infect Dis J. 2005;24(6 suppl):S134-S140.
41. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule, United States, 2006. Available at: http://www. cdc.gov/nip/recs/child-schedule-color-print.pdf/. Accessed October 2, 2006.
42. Davis MM, Gaglia M. Association of daycare and school entry vaccination requirements with varicella immunization rates. Vaccine. 2005;23:3053-3060.
43. Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA. The impact of a school entry law on adolescent immunization rates J Adolesc Health. 2005;37:511-516.
44. Newacheck PW, Park MJ, Brindis CD, Biehl M, Irwin CE Jr. Trends in private and public health insurance for adolescents. JAMA. 2004;291: 1231-1237.
45. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005;37:502-510.
46. Mays RM, Zimet GD. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis. 2004;31:428-432.
47. Raley JC, Followwill KA, Zimet GD, Ault KA. Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists. Infect Dis Obstet Gynecol. 2004;12:127-133.
48. Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol. 2005; 18:391-398.
49. CDCs Advisory Committee Recommends Human Papillomavirus Vaccination [press release]. Atlanta, Ga: Centers for Disease Control and Prevention; June 29, 2006. Available at: http://www.cdc.gov/od/oc/media/ pressrel/r060629.htm? s_cid=mediarel_r060629_x. Accessed November 22, 2006.
50. Dillner J. HPV type replacement in the post-vaccination era. What is meant and is it likely? Eur J Obstet Gynecol Reprod Biol. 2006. In press.
51. Gardasil [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2006.
52. Rupp R, Rosenthal SL, Middleman AB. Vaccination: an opportunity to enhance early adolescent preventative services. J Adolesc Health. 2006;39:461-464.